Latest Conference Articles

In an ideal world, interventions would have a pilot study before RCT.

Which recommendations decrease asthma morbidity in children with asthma?

Matthew Perzanowski, PhD, discusses allergic asthma environmental factors.

Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.

One team's goal at the US Military HIV research Program is to control plasma viral load in the blood to undetectable levels without the use of long-term ART.

"We've done a really good job of developing medicines to get that virus under control. I think what's sort of important for our community now is to very carefully look at what the unmet needs are," said Emu.

Adding an extra 20,000 IU vitamin D2 a week didn't make a difference.

"Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.

HIV, hepatitis C coinfections weren't all that uncommon at a Bronx ER.

The CDC says that more than 40% of chlamydia and gonorrhea cases can be prevented.

The idea of holistic care has two meanings, Anthony Mills, MD, SoCal Men's Medical Group, explained at CROI 2017.

At CROI 2017, James McIntyre, MBChB, Anova Health Institute explained that HIV prevention remains one of the most important things researchers still have to deal with.

CDC officials break down annual HIV infections in a new analysis.

HIV-positive men who have sex with men or women are at risk for HPV.

Published literature says the pre-seroconversion window period lasts around 45 days.

Hepatitis C screening based only on risk factors could miss infected people.

James McIntyre, MBChB, FRCOG, continued to discuss the key success story in HIV prevention history: preventing transmission from mothers to babies. Many papers report that transmission has dropped to less than 2%, and across Africa transmission has dropped from 18% to less than 6%.

Study addresses one of the biggest challenges with HIV preventive drug.

Kathleen Squires, MD, announces positive trial results for an investigational HIV drug.

Two-drug HIV regimen performs well against three- or four-drug regimens.

At CROI 2017, John W. Ward, MD, CDC, explained his team has been concentrating on one particular health effect: transmission of hepatitis C from mother-to-child at the time of birth. This is showing them increases in children now becoming infected with hepatitis C, so it’s a growing problem among young people and their children.

We've had a 150% increase in the number of new cases of hepatitis C in the country, and almost all of those cases are among persons less than 30 years of age," John W. Ward, MD, of CDC said.

"We have drugs now that used to take one pill to several pills a day for 2-3 months, you can cure 95% of people living with hepatitis C. The issue is getting those persons identified who are living with this silent infection."

A much-anticipated investigational HIV drug has phase 2 results.

In a study announced at the 2016 American College of Rheumatology Annual Meeting in Washington, DC, lupus patients with less education were also likely to wait longer for referral to a specialist.

“This is a subset of the RA population that we should probably give intensive treatment to," Dr. Harrold says of RA patients diagnosed with certain prognosis factors. "Not only clinical adverse sequelae, but also in their social environment, like being able to work or function.”

Since they were first approved for patient care more than a year ago PCSK9 inhibitors have shown to be a powerful tool in the fight against dangerously high cholesterol levels. However, there are still challenges standing in the way of them being made more widely available.

The annual American Heart Association Scientific Sessions were filled with a wide range of presentations made in New Orleans. It was the late breaking news that made the most impact for those in attendance as they look to the future of cardiac care.

As the American Heart Association wrapped up another successful conference in New Orleans, each of the approximately 18,000 providers in attendance was bringing home something new to their practices or optimism for new treatments to come in the future.